• slide1.jpg
  • slide2.jpg
  • slide3.jpg
  • slide4.jpg

Board of Directors

President: Tracy Stockley, PhD, FCCMG

Research location: Toronto General Hospital/Research Institute (UHN)
Primary Research Area: Genetics, Genomics & Proteomics
Secondary Research Area: Cancer
Research Statement:

Dr. Stockley’s research interests include development of genomic tests for molecular diagnostics, application of new technologies such as Next-Generation Sequencing to clinical care for acquired and inherited disease, and quality management for high-complexity clinical laboratory testing.

Secretary: Tanya Nelson, PhD, FCCMG

NelsonT photoDr. Tanya Nelson is a clinical Molecular Geneticist and Head of the Division of Genome Diagnostics at the BC Children’s and BC Women’s Hospitals, and a UBC Clinical Professor in the Department of Pathology & Laboratory Medicine. As a Chair or member of CCMG committees, Dr. Nelson has collaborated on numerous guideline and position statements, both in the prenatal and postnatal setting. She is also actively involved in CCMG training, and is the Director of the UBC CCMG Molecular Genetics post-graduate fellowship program.

 Treasurer: Marjan Nezarati, MD, FRCPC, FCCMG

 Member/Secretary Elect: Murray Potter, MD, FRCPC, FCCMG

http://fhs.mcmaster.ca/pathology/images/potter-2012.jpgProfessor, Department of Pathology and Molecular Medicine, McMaster University

Dr. Potter spends most of his professional time in the area of biochemical genetics and newborn screening. Direct clinical duties include running Metabolic Genetic and Newborn Screening clinics at McMaster Children's Hospital and directing the Biochemical Genetics Laboratory at the Hamilton Regional Laboratory Medicine Program.

The major focus of Dr. Potter’s research is on inborn errors of metabolism. This encompasses clinical research in the diagnosis and management of these disorders and the development of new/improved mass-spectrometry diagnostic and monitoring tests. Dr. Potter’s educational contributions include undergraduate, medical student and post-graduate teaching at McMaster University. He is also involved in local education administration (Associate Chair Education, Department of Pathology and Molecular Medicine) and national assessment (Royal College of Physicians and Surgeons and Canadian College of Medical Geneticists examinations).

Member at Large: Linlea Armstrong, BSc, MD, FRCPC, FCCMG

armstrong2Provincial Medical Genetics Programme, BC Women's Hospital
Linlea Armstrong is a Clinical Geneticist who cares for individuals and families with genetic and genomic concerns.  Passionate about working with learners and finding ways to optimize the training of future health care providers, she serve as Clinical Education Director within her department, which encompasses the responsibilities of Program Director for the Royal College residency program, Medical Director for the Masters of Genetic Counselling program, and Theme Lead for the Genetics and Genomics Theme in the MD Undergraduate Program.

Member at Large: Elizabeth (Beth) Spriggs, PhD, FCCMG

spriggsFor the past 20 years, Beth has worked as a clinical Molecular Geneticist at the Winnipeg Health Sciences Centre. She was recently appointed as the Associate Medical Director of the recently expanded Genomics Discipline within the non-profit provincial organization, Shared Health. Beth is also cross-appointed to the Rady Faculty of Health Sciences in the University of Manitoba as an Assistant Professor.  She has been involved with the CCMG since 1998 and has served as a member of the Molecular Genetics, Education, Accreditation of Centres, and Examinations Committees. She is also actively involved in the education of graduate students including those in Manitoba’s new Masters of Genetic Counselling program, RCPSC residents, and CCMG post-graduate trainees.

Member at LargeElizabeth (Liz) McCready, PhD, MSc, FCCMG

mccready2Dr. McCready is an Associate Professor in the Department of Pathology and Molecular Medicine at McMaster University and Head of Molecular Cytogenetics within the Hamilton Regional Laboratory Medicine Program (HRLMP) Genetics Laboratories.  She is dual certified through the CCMG in Molecular Genetics (2006) and Cytogenetics (2008) and has been active with the CCMG through involvement in several standing and ad hoc committees.  She is currently the Program Director for the CCMG Genetics Fellowship Training Program through the Postgraduate Pathology and Molecular Medicine Program at McMaster University. 

Member at LargeIsabelle De Bie, MD, PhD, FRCPC, FCCMG

debieDr. Isabelle De Bie is a Clinical and Molecular Geneticist. She initially trained in Biochemistry, Immunology, then Molecular Biology, before undertaking her Royal College training in Medical Genetics, followed by a CCMG fellowship in Molecular Genetics.
She currently heads the prenatal diagnosis program and acts as clinical director of the Core Diagnostic Molecular Laboratory at the McGill University Health Centre. Her areas of interest span both pre and postnatal dysmorphology, in particular skeletal dysplasias.
She contributed to several guidelines and positions statements as a member of the CCMG Clinical Practice committee and as CCMG representative to the SOGC Genetics committee.
She is a supporter of the international “Choosing Wisely” campaign, which advocates for clinically relevant medical care.

Past - President: Judy Chernos, PhD, FCCMG

Judy Chernos is an Associate Professor in the Department of Medical Genetics, University of Calgary and is a senior Cytogeneticist at the Alberta Children’s Hospital.  She obtained her BSc in Zoology and Anthropology from the University of Toronto.  After moving west, she completed a PhD from the University of Calgary in Medical Genetics (1988) examining the effects of cryopreservation on chromosomal anomalies in gametes, followed by CCMG post-doctoral training in Cytogenetics.  She has been a Fellow of the CCMG since 1991.  Dr. Chernos is a keen educator at all levels.  Her longstanding scientific interest is in elucidating the nature of unique constitutional chromosome anomalies using traditional and genomic technologies and correlating with clinical phenotypes.